JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osborne, M. W.
Right arrow Articles by Winbury, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osborne, M. W.
Right arrow Articles by Winbury, M. M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 147, Issue 2, 212-224, 1965
Copyright © 1965 by American Society for Pharmacology and Experimental Therapeutics

QUINDONIUM BROMIDE—SOME ASPECTS OF THE CARDIOVASCULAR PHARMACOLOGY

Melville W. Osborne 1 and Martin M. Winbury 1

1 Department of Pharmacology, Warner-Lambert Research Institute, Morris Plains, New Jersey

The pharmacological evaluation of quindonium bromide shows that the dominant cardiovascular effects are a positive inotropism, bradycardia and vasodilatation. In addition there is an indirect cholinergic action on the gut. These combined properties do not identify quindonium as belonging to any known class of pharmacological agents.

Quindonium has a positive inotropic effect in both intact and isolated myocardial preparations; this action was blocked by nethalide in the isolated papillary muscle. The bradycardia is not mediated through a vagal mechanism. Vasodilatation is not associated with any known drug action. It does not appear to involve beta-adnenergic, cholinergic or histaminergic mechanisms.

The quindonium reversal of both drug and spontaneously induced cardiovascular depression indicates a possible therapeutic use in clinical shock and heart failure syndromes.

Accepted on October 20, 1964






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics.